What's the goal of the project, is it to produce cheap insulin, or is it to validate "open-source biohacking"? If it's the latter, why start with such a hard m

What's the goal of the project, is it to produce cheap insulin, or is it to validate "open-source biohacking"? If it's the latter, why start with such a hard molecule; isn't there a lower-hanging fruit? If it's the former, it would seem grounded in the assumption that biosimilar insulin unavailability in the Western markets is due to the lack of a royalty-free production method. I'm not sure that is the case (and please, correct me along the way). Biosimilars face a more rigorous/expensive approval process than generics (as they should), they're more expensive to produce under GxP conditions, and they're more expensive to store/transport/etc—the upfront costs are higher, the production costs are higher, and the logistical costs are higher. A small portion of NRE costs in the beginning would seem to be a drop in the bucket compared to the rest. Are you planning to address the rest of the lifecycle? Also, there would seem to be a lot of handwaving over the folding problem… do you have direct plans to address it? I don't intend for this to come across harshly—I'm genuinely curious and hope this comes across constructively.